{
    "clinical_study": {
        "@rank": "126018", 
        "arm_group": [
            {
                "arm_group_label": "BOTOX\u00ae", 
                "description": "Retrospective chart review of doses of BOTOX\u00ae (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered."
            }, 
            {
                "arm_group_label": "Xeomin\u00ae", 
                "description": "Retrospective chart review of doses of Xeomin\u00ae (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a retrospective chart review to evaluate the doses of  botulinum Type A toxins\n      BOTOX\u00ae (onabotulinumtoxinA) and Xeomin\u00ae (incobotulinumtoxinA) used for the treatment of\n      Cervical Dystonia and Blepharospasm in clinical practice."
        }, 
        "brief_title": "A Retrospective Chart Review of BOTOX\u00ae and Xeomin\u00ae for the Treatment of Cervical Dystonia and Blepharospasm", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cervical Dystonia", 
            "Blepharospasm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blepharospasm", 
                "Dystonia", 
                "Dystonic Disorders", 
                "Torticollis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at\n             least 2 years\n\n          -  treatment with Xeomin\u00ae and BOTOX\u00ae for at least 1 year each\n\n        Exclusion Criteria:\n\n          -  having a neuromuscular junction transmission disorder or taking any medications  that\n             could affect neuromuscular junction transmission\n\n          -  previous surgical procedure involving bone or muscle for the management of cervical\n             dystonia or blepharospasm"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants with cervical dystonia or blepharospasm previously treated with Xeomin\u00ae and\n        BOTOX\u00ae."
            }
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814774", 
            "org_study_id": "TRU2011"
        }, 
        "intervention": {
            "arm_group_label": [
                "BOTOX\u00ae", 
                "Xeomin\u00ae"
            ], 
            "description": "No treatment (intervention) was administered.", 
            "intervention_name": "No Intervention", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bergen", 
                        "country": "Norway"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wakefield", 
                        "country": "United Kingdom"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Norway", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "2", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "Norway: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Dose of Botulinum Toxin Used to Treat Cervical Dystonia", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "measure": "Dose of Botulinum Toxin Used to Treat Blepharospasm", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814774"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "No", 
            "time_frame": "1 Year"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}